The Trade Desk TTD

Ventura, California-based The Trade Desk (TTD) operates as a global digital advertising tech company across CTV, video, display, audio, and native formats. It has about a $6 billion market cap. The stock is roughly 77.5% below its 52-week high of $56.39 set Oct. 7, 2025, and has fallen 29.3% in the past three months, underperforming the XLC ETF's 4.9% gain. Over 52 weeks, TTD is down about 72.9% versus XLC's 4.9% decline. The shares have traded below their 200-day and 50-day moving averages since last year, signaling bearish momentum. On Aug. 7, TTD dropped 21.9% after weaker Q2 2026 results: revenue $715.1 million, adjusted EPS $0.34, and margins thinning (operating margin 14.2%). Q3 guided around $650 million, below estimates due to execution and macro pressures. Analysts rate it Hold with a $13.63 target (about 7.5% upside). Q2 miss, downbeat guidance, and margin erosion indicate meaningful near-term headwinds and negative sentiment.

TTD, a key digital-advertising platform, is drawing attention from Zacks.com as investors weigh near-term trends. The stock fell 2.7% in the past month, versus the S&P 500’s 1.3% rise and a 1.2% gain for the Internet-Services group. Current-quarter earnings are expected at $0.27 per share, -40% YoY, with a 4.4% upward revision over the last 30 days. For the full year, consensus EPS is $1.22 (down 31.1% YoY); next year’s is $1.20 (down 1.5%). Revenue projections show declines: current quarter $650.7 million (-12%); full-year $2.84 billion (–2%); next year $2.79 billion (–1.7%). The last four quarters saw just one EPS beat and three misses on revenue. Zacks ranks TTD #4 (Sell), signaling potential near-term underperformance despite an A Value score. Earnings and revenue revisions point to near-term weakness and Zacks' Sell rank suggests potential underperformance.

Trade Desk’s share price has fallen about 82% over three years, raising questions whether the current price around $13 reflects the cash the business can generate. A discounted cash flow model points to an intrinsic value well above the market price, based on trailing free cash flow of roughly $897 million and forecasts of a continued cash-generating path over the next decade. Recent healthcare and connected-TV partnerships—with Veeva Crossix, IQVIA Digital, and Telly’s programmatic home-screen marketplace—are cited as indicators of faster monetization of media spend into future cash flows. On earnings, the stock trades near a 15.3x P/E, suggesting a different valuation story. The piece also notes valuation depends on leadership decisions and compensation alignment with long-term goals. This analysis is informational and not financial advice; Simply Wall St has no position in TTD. Strategic healthcare partnerships and a growing free cash flow trajectory suggest a meaningful upside not yet priced in.

TTD is deepening its foray into healthcare advertising by integrating OptimizeRx’s authenticated point-of-care inventory into its OpenPath platform. Advertisers using The Trade Desk will gain direct access to OptimizeRx’s HCP inventory across more than 400 EHR and e-prescribing systems, reaching about 800,000 verified healthcare professionals. The inventory is slated to become available via OpenPath in Q4 2026, reducing intermediaries in the supply chain and streamlining media planning for life sciences campaigns. The move complements recent expansions of TTD’s healthcare capabilities through tighter integrations with Veeva Crossix and IQVIA Digital, enabling more granular measurement signals within the platform. The partnership could attract pharmaceutical advertisers and shift additional budget toward authenticated HCP and point-of-care placements, potentially increasing TTD’s share of healthcare programmatic advertising. Expands authenticated HCP inventory and healthcare integrations, likely lifting healthcare programmatic growth and competitive positioning.

AppLovin reported Q2 2026 revenue of $1.92 billion, up 53% year over year, but growth has slowed for three consecutive quarters. Management blamed lighter-than-normal model improvements; the next upgrade landed just after the quarter ended. Gaming remains the majority of revenue, with model performance the main growth driver. Guidance for Q3 2026 shows continued slower growth, with a top-end around 48% YoY. Higher compute costs accompany revenue growth, contributing to rising expenses. The stock has fallen about 49% in the past year, and a securities class action has been filed over model progress. Valuation remains rich—about 16.2x trailing revenue and 25x earnings. Advertisers spent a record amount on AppLovin's platform in Q2, but timing issues with model releases dampened revenue. The third quarter started strong; a lead-plaintiff deadline is November 16, 2026. Slower growth at a peer in the ad-tech space could influence market sentiment around the sector but is unlikely to drastically alter TTD's trajectory.

OptimizeRx announces an integration with OpenPath, The Trade Desk's supply path optimization solution, to make OptimizeRx’s authenticated point-of-care inventory from more than 400 EHR and e-prescribe systems available directly to advertisers using The Trade Desk. The network covers about 800,000 verified healthcare professionals. The move aims to bring point-of-care inventory into mainstream programmatic buying, expanding access beyond direct or healthcare-specific platforms and enabling in-workflow ad placements within life sciences campaigns. OpenPath promises transparent access to premium publisher inventory, and OptimizeRx emphasizes maintaining verified providers, real clinical workflows, and proximity to treatment decisions. Availability with The Trade Desk is expected in Q4 2026. Access to authenticated HCP inventory via OpenPath could meaningfully boost The Trade Desk’s healthcare demand and vertical growth.

OptimizeRx's authenticated EHR/prescription network spans 400+ systems and 800,000 verified healthcare professionals. It will integrate with OpenPath, The Trade Desk's supply-path optimization, enabling advertisers using The Trade Desk DSP to access OptimizeRx's point-of-care inventory. The alliance shifts EHR advertising from traditional direct-managed deals toward programmatic buying and broadens reach for life sciences advertisers. Inventory is expected to be available through OpenPath in Q4 2026. CEO Stephen Silvestro said the integration broadens access to verified clinical inventory; The Trade Desk's Baron Harper says it gives life sciences advertisers more choice. The move is part of OptimizeRx's broader programmatic distribution strategy to create multiple buyer entry points and tap new advertiser demand. OPRX rose about 1%; TTD fell roughly 4%. Expands OpenPath-enabled healthcare inventory into The Trade Desk's DSP, broadening potential demand but with a multi-quarter timeline and still-developing monetization.

Trade Desk falls 4% as index-removal flows force passive selling after moving from the S&P 500 to the SmallCap 600; Magnite drops 3% while AppLovin is largely unchanged. With SPY flat and IWM up, the ad-tech decline looks driven by programmatic-specific pressure, not broad market weakness. TTD now trades around 13x trailing earnings and has 95% plus customer retention, but the valuation hinges on whether next-quarter results sustain the high-margin platform thesis. The move appears rebalance-driven rather than due to new fundamentals. Magnite's decline alongside TTD versus AppLovin's stability suggests rotation within ad-tech rather than a sector-wide rout. Analysts note passive flows should exhaust after the rebalance, and buyers would need to re-rate TTD's earnings power to lift the multiple. Near-term pressure is driven by index-rebalance selling, with longer-term upside contingent on next-quarter earnings and sustained retention.

The Trade Desk (TTD) trades near $13.92, with a mean Street target around $13.60 and a mid target near $23, implying ~65% total return and ~12% IRR from today. Revenue and earnings have deteriorated; Q2 revenue rose 3% to $715M and missed estimates, while adj. EPS was $0.34 vs $0.40. Q3 guidance called for at least $650M in revenue, implying a ~12% year-over-year decline. CEO Jeff Green cited macro pressures in CPG and auto ads and said execution could have been better. On Sep 3, TTD cut about 575 jobs (roughly 15%), with $39–$51M charges in Q3, and the stock was dropped from the S&P 500 into the SmallCap 600. CFO Nate Olmstead framed a disciplined plan: invest where returns are attractive and cut elsewhere. A stabilizing top line and ongoing cost discipline could lift margins and valuation, but macro weakness remains a risk. Cost cuts and margin protection could materially improve profitability if revenue stabilizes, potentially altering valuation and sentiment.

TTD unveiled a 15% workforce reduction and expects Q3 revenue around $650 million, down about 12% year over year. Growth has decelerated—from 18% in Q3 2025 to 14% in Q4 2025, 12% in Q1 2026, and only 3% in Q2 2026—while Q3 non-GAAP EBITDA is guided at about $160 million, down from $317 million a year earlier. Net income in Q2 fell ~29%. Management cites limited visibility and no meaningful ad-market improvement. The layoffs aim to trim costs but cannot restore ad spending, with advertisers like CPG and auto under pressure from tariffs and oil prices; competition from Amazon’s platform is rising. The stock trades around $14, roughly 90% below its December 2024 high, with about $1.5 billion in cash. Retention remains strong (>95%), but investors will want rising revenue and stable margins before valuing a turnaround as a bargain. Guidance shows declining revenue and EBITDA along with layoffs, signaling material near-term deterioration in growth and profitability that could shift investor sentiment.

Over five years, The Trade Desk returned about $2.5 billion to shareholders via buybacks, equal to 38% of its current market value but only 5.7% of its value at the start of the window. The stock fell 81% in that period, while the SPY rose about 83%. Free cash flow remains robust (about $0.85 billion trailing twelve months on a ~19.6% operating margin), but buybacks did little to lift the share price in a slowing growth environment. Management warned that revenue growth is below expectations amid macro headwinds and execution misses, and advertisers are favoring cheaper media. The key test is whether growth from large JBPs with core clients and product upgrades like Audience Unlimited can re-accelerate revenue; if not, the cash returns look like a consolation prize. Buybacks help but do not offset ongoing growth deterioration, making JBPs and new products the crucial near-term driver.

The Trade Desk expands healthcare data partnerships as questions linger over whether its stock remains undervalued. Healthcare data expansion may moderately strengthen The Trade Desk market reach and investor sentiment without major trajectory shifts.

Morningstar predicts The Trade Desk will lose market share to Amazon, Google, and Meta as they ramp up advertising competition. Rising ad competition from Amazon, Google, and Meta is expected to shrink The Trade Desk market share and hurt its performance.

TTD expands pharma reach through new healthcare integrations with potential to drive growth. New healthcare integrations may moderately influence TTD's market position and performance.

AppLovin holds a competitive lead over peers including The Trade Desk, but market pricing may already reflect this advantage, limiting upside potential for AppLovin relative to TTD. Questions over whether AppLovin's edge versus TTD is priced in could moderately shift investor views on TTD's relative positioning.

The Trade Desk's substantial cash holdings face scrutiny against its decelerating growth, raising questions on whether reserves can offset lost momentum in ad tech market share and valuation. Slowing growth directly pressures TTD valuation and competitive standing despite cash buffer.

The Trade Desk expands healthcare measurement and optimization integrations for pharma advertisers. Healthcare integration expansion targets pharma sector for moderate operational growth without major trajectory shifts.

Trade Desk adds in-workflow brand lift measurement across global markets. Global rollout of measurement feature strengthens TTD product suite and market position.

The Trade Desk considers Audience Unlimited as a potential accelerator for its growth momentum. Audience Unlimited represents a potential new growth avenue for The Trade Desk.

The Trade Desk pursues international expansion across EMEA and APAC regions as a potential driver of future growth. EMEA and APAC expansion efforts may moderately shape The Trade Desk growth path without guaranteed major shifts.

Three catalysts may reverse The Trade Desk's recent stock decline and restore performance. Mentioned catalysts represent strategic moves likely to significantly shift company trajectory and investor sentiment.

September 21 is a key date for The Trade Desk investors to watch for an upcoming event that may move the stock. September 21 represents a scheduled event likely to produce moderate short-term effects on TTD trading and sentiment.

The Trade Desk plans to cut 15% of its workforce. The article outlines steps needed for TTD stock to rebound. 15% workforce reduction signals cost restructuring that may affect near-term operations and sentiment but leaves long-term trajectory largely intact.

The Trade Desk initiates major reset after 70% stock decline. Major reset after severe decline signals strategic overhaul likely to reshape company trajectory and investor sentiment.

S&P 500 adds Bloom Energy and removes Trade Desk. Bloom Energy shares jump 8%. TTD shares drop 2%. S&P 500 removal triggers index fund selling and reduces TTD visibility.

TTD stock features an unusual cash offer that presents a specific investment angle for shareholders amid current market conditions. Cash offer creates moderate short-term trading interest without altering TTD's core ad-tech business trajectory.

The Trade Desk cuts 15% of workforce. 15% workforce reduction signals cost adjustments that may influence near-term operations and sentiment without redefining long-term trajectory.

Fair competition requires a level starting line in digital advertising markets because even leading firms like The Trade Desk can lose ground when conditions favor incumbents. Talk of competitive fairness points to possible regulatory or platform shifts that could moderately reshape The Trade Desk's positioning versus larger rivals.

TTD stock declined after Wall Street split on 15% job cuts. Rosenblatt sees cost relief while Jefferies flags top-line risk. 15% job cuts create analyst split on costs versus revenue that may moderately affect near-term results.

The Trade Desk announces layoffs after disappointing financial reports, triggering a stock decline. Layoffs following weak results point to operational strain likely to influence near-term performance and sentiment.